{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:20:28Z","timestamp":1785320428839,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Due to new advances in molecular and imaging biomarkers, a biological classification of Parkinson\u2019s disease (PD) called SyNeurGe (Hoglinger et al. Lancet Neurol 2024;23:191-204) has been proposed for research use recently. [<jats:sup>123<\/jats:sup>I]ioflupane dopamine transporter single-photon-emission-computed tomography (DaT-SPECT) and cardiac [<jats:sup>123<\/jats:sup>I]meta-iodobenzylguanidine (MIBG) scintigraphy are included in this biological classification scheme together with 2-[<jats:sup>18<\/jats:sup>F]fluoro-2-deoxy-D-glucose (FDG-PET) as central imaging biomarkers for the assessment of dopaminergic function, cardiac sympathetic denervation, and metabolic patterns in brain. In order to facilitate this prospectively high imaging demand and optimize diagnostic workup in PD we propose a single-day protocol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>First, we excluded relevant binding of MIBG in the brain as well as DaT in the heart by acquisition of brain scans in patients that received MIBG as well as by acquisition of chest scans in patients that received DaT. Then, we performed a single-day protocol including DaT-SPECT and cardiac MIBG scintigraphy in ten patients with clinically suspected \u03b1-synucleinopathies (9 male, 1 female; 68.2\u2009\u00b1\u20097.3\u00a0years). Both radiotracers were injected simultaneously and cardiac imaging was performed at 3.5\u00a0h after injection followed by brain imaging at 4\u00a0h after injection using standard protocols for MIBG-scintigraphy and DaT-SPECT. Additionally, five patients of the dual tracer protocol group received brain FDG-PET after DaT and MIBG imaging.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Single tracer imaging confirmed no relevant uptake of [<jats:sup>123<\/jats:sup>I]ioflupane in the heart or [<jats:sup>123<\/jats:sup>I]MIBG in the brain. Six out of the ten dual tracer protocol patients (PD or multiple system atrophy with Parkinsonian phenotype (MSA-P)) showed a significantly reduced DaT-SPECT binding (z-score\u2009&lt;\u2009-2) in at least one hemisphere (mean putaminal z-score -4.01\u2009\u00b1\u20091.39) while seven patients had a pathological heart-to-mediastinum ratio in the MIBG scan (mean H\/M-ratio: 1.12\u2009\u00b1\u20090.08). Both DaT and MIBG scans could visually be interpreted without any signs of image artifacts or decrease in imaging quality and also quantitatively did not reveal significant differences to the single tracer scans. FDG-PET brain scans of the triple tracer protocol patients also showed no relevant interference in regard to image quality as well was generation of surface projections and z-scores.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A single day protocol for DaT-SPECT, MIBG, and FDG-PET facilitates biomarker assessments needed for efficient biological characterization of Parkinsonian syndromes according to the SyNeurGe criteria.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07188-0","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T02:50:22Z","timestamp":1741661422000},"page":"3424-3432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders"],"prefix":"10.1007","volume":"52","author":[{"given":"Maximilian","family":"Scheifele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Gn\u00f6rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Kunte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Ells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Katzdobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Palleis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"J\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Franzmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"7188_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1988;51:745\u201352. https:\/\/doi.org\/10.1136\/jnnp.51.6.745.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7188_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","volume":"9","author":"M Goedert","year":"2013","unstructured":"Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9:13\u201324. https:\/\/doi.org\/10.1038\/nrneurol.2012.242.","journal-title":"Nat Rev Neurol"},{"key":"7188_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23:191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0.","journal-title":"Lancet Neurol"},{"key":"7188_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23:178\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"key":"7188_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3:812\u20138. https:\/\/doi.org\/10.1002\/acn3.338.","journal-title":"Ann Clin Transl Neurol"},{"key":"7188_CR6","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/mds.28242","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne S, Kondru N, Jin H, Serrano GE, Anantharam V, Kanthasamy A, et al. Blinded RT-QuIC Analysis of alpha-Synuclein Biomarker in Skin Tissue From Parkinson\u2019s Disease Patients. Mov Disord. 2020;35:2230\u20139. https:\/\/doi.org\/10.1002\/mds.28242.","journal-title":"Mov Disord"},{"key":"7188_CR7","doi-asserted-by":"publisher","first-page":"e6967","DOI":"10.1097\/MD.0000000000006967","volume":"96","author":"S Nuvoli","year":"2017","unstructured":"Nuvoli S, Spanu A, Piras MR, Nieddu A, Mulas A, Rocchitta G, et al. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders. Medicine (Baltimore). 2017;96:e6967. https:\/\/doi.org\/10.1097\/MD.0000000000006967.","journal-title":"Medicine (Baltimore)"},{"key":"7188_CR8","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885\u2013912. https:\/\/doi.org\/10.1007\/s00259-020-04817-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7188_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","volume":"49","author":"E Guedj","year":"2022","unstructured":"Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632\u201351. https:\/\/doi.org\/10.1007\/s00259-021-05603-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7188_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","volume":"23","author":"MJ Henzlova","year":"2016","unstructured":"Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016;23:606\u201339. https:\/\/doi.org\/10.1007\/s12350-015-0387-x.","journal-title":"J Nucl Cardiol"},{"key":"7188_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10286-011-0135-5","volume":"22","author":"G Treglia","year":"2012","unstructured":"Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43\u201355. https:\/\/doi.org\/10.1007\/s10286-011-0135-5.","journal-title":"Clin Auton Res"},{"key":"7188_CR12","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.nuclcard.2024.101911","volume":"39","author":"JM Hagen","year":"2024","unstructured":"Hagen JM, Zacherl MJ, Brendel M, Clauss S, Kaab S, Bartenstein P, et al. Quantitative assessment of cardiac (123)iodo-metaiodobenzylguanidine SPECT\/CT in patients with arrhythmogenic right ventricular cardiomyopathy: Novel insight in disease monitoring. J Nucl Cardiol. 2024;39:101911. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.101911.","journal-title":"J Nucl Cardiol"},{"key":"7188_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10072-003-0103-5","volume":"24","author":"A Antonini","year":"2003","unstructured":"Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, et al. 123I-Ioflupane\/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149\u201350. https:\/\/doi.org\/10.1007\/s10072-003-0103-5.","journal-title":"Neurol Sci"},{"key":"7188_CR14","doi-asserted-by":"publisher","unstructured":"Palermo G, Ceravolo R. Molecular Imaging of the Dopamine Transporter. Cells. 2019;8. https:\/\/doi.org\/10.3390\/cells8080872","DOI":"10.3390\/cells8080872"},{"key":"7188_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13550-023-00978-3","volume":"13","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wang Y, Wang J, Li X, Li B. Safety, biodistribution and radiation dosimetry of [(123)I]ioflupane in healthy Chinese volunteers. EJNMMI Res. 2023;13:30. https:\/\/doi.org\/10.1186\/s13550-023-00978-3.","journal-title":"EJNMMI Res"},{"key":"7188_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.taap.2004.08.013","volume":"204","author":"MJ Bannon","year":"2005","unstructured":"Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204:355\u201360. https:\/\/doi.org\/10.1016\/j.taap.2004.08.013.","journal-title":"Toxicol Appl Pharmacol"},{"key":"7188_CR17","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1523\/JNEUROSCI.14-08-04903.1994","volume":"14","author":"D Lorang","year":"1994","unstructured":"Lorang D, Amara SG, Simerly RB. Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci. 1994;14:4903\u201314. https:\/\/doi.org\/10.1523\/JNEUROSCI.14-08-04903.1994.","journal-title":"J Neurosci"},{"key":"7188_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.tips.2013.07.005","volume":"34","author":"RA Vaughan","year":"2013","unstructured":"Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci. 2013;34:489\u201396. https:\/\/doi.org\/10.1016\/j.tips.2013.07.005.","journal-title":"Trends Pharmacol Sci"},{"key":"7188_CR19","first-page":"672","volume":"24","author":"M Nakajo","year":"1983","unstructured":"Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med. 1983;24:672\u201382.","journal-title":"J Nucl Med"},{"key":"7188_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/s0001-2998(05)80157-6","volume":"22","author":"MT Parisi","year":"1992","unstructured":"Parisi MT, Sandler ED, Hattner RS. The biodistribution of metaiodobenzylguanidine. Semin Nucl Med. 1992;22:46\u20138. https:\/\/doi.org\/10.1016\/s0001-2998(05)80157-6.","journal-title":"Semin Nucl Med"},{"key":"7188_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/BF00173043","volume":"21","author":"AR Wafelman","year":"1994","unstructured":"Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545\u201359. https:\/\/doi.org\/10.1007\/BF00173043.","journal-title":"Eur J Nucl Med"},{"key":"7188_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/00003072-199807000-00009","volume":"23","author":"BA Dwamena","year":"1998","unstructured":"Dwamena BA, Zempel S, Klopper JF, Van Heerden B, Wieland D, Shapiro B. Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma. Clin Nucl Med. 1998;23:441\u20135. https:\/\/doi.org\/10.1097\/00003072-199807000-00009.","journal-title":"Clin Nucl Med"},{"key":"7188_CR23","doi-asserted-by":"publisher","unstructured":"Hagen JM, Scheifele M, Zacherl MJ, Katzdobler S, Bernhardt A, Brendel M, et al. Diagnostic Efficacy of (123)Iodo-Metaiodobenzylguanidine SPECT\/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and alpha-Synucleinopathies. Diagnostics (Basel). 2024;15. https:\/\/doi.org\/10.3390\/diagnostics15010024","DOI":"10.3390\/diagnostics15010024"},{"key":"7188_CR24","first-page":"753","volume":"40","author":"J Booij","year":"1999","unstructured":"Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson\u2019s disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753\u201361.","journal-title":"J Nucl Med"},{"key":"7188_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jnnp.62.2.133","volume":"62","author":"J Booij","year":"1997","unstructured":"Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1997;62:133\u201340. https:\/\/doi.org\/10.1136\/jnnp.62.2.133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7188_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jcmg.2009.07.014","volume":"3","author":"I Carrio","year":"2010","unstructured":"Carrio I, Cowie MR, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging. 2010;3:92\u2013100. https:\/\/doi.org\/10.1016\/j.jcmg.2009.07.014.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7188_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13139-023-00790-w","volume":"57","author":"IK Chun","year":"2023","unstructured":"Chun IK. Optimal Protocol and Clinical Usefulness of (123)I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson\u2019s Disease and Dementia with Lewy Body from Non-Parkinson\u2019s Diseases. Nucl Med Mol Imaging. 2023;57:145\u201354. https:\/\/doi.org\/10.1007\/s13139-023-00790-w.","journal-title":"Nucl Med Mol Imaging"},{"key":"7188_CR28","doi-asserted-by":"publisher","unstructured":"Pitton Rissardo J, Fornari Caprara AL. Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review. Brain Sci. 2023;13. https:\/\/doi.org\/10.3390\/brainsci13101471","DOI":"10.3390\/brainsci13101471"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07188-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:27Z","timestamp":1751435547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07188-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7188"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07188-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for SPECT and PET imaging. The study was carried out according to the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Maximilian Scheifele:none.Johannes Gn\u00f6rich:none.Sophie Kunte:none.Zachary Ells:none.Johannes Hagen:none.Sabrina Katzdobler:none.Carla Palleis:no competing interests, funding: Thiemann Foundation, Else-Kr\u00f6ner-Fresenius FoundationAlexander Bernhardt:none.Alexander J\u00e4ck:none.Nicolai Franzmeier:none.Maximilian Fischer: none.Johannes Levin:none.G\u00fcnter U. H\u00f6glinger:none.Rudolf A. Werner:none.Matthias Brendel:Member of the Neuroimaging Committee of the EANM. Received speaker honoraria from Roche, GE Healthcare, and Life Molecular Imaging and served as an advisor of MIAC and Life Molecular Imaging.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}